Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

Growth stocks are getting hammered by soaring bond yields. First off, long-dated bond yields have taken a wrecking ball to ...

The list includes several groundbreaking therapies that are expected to change the treatment landscape for several diseases and conditions.

After Vertex President and CEO Reshma Kewalramani presented at the firm’s healthcare conference, JPMorgan analyst Jessica Fye notes that the ...

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

Amazon Few companies enjoy as strong of a competitive moat as Amazon (NASDAQ: AMZN). Actually, Amazon has multiple strong moats. There's a networking moat with the company's e-commerce platform ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...

A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).